Cargando…
Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model
The low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen is an effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). G-CSF influences the bone marrow microenvironment...
Autores principales: | Chen, Jinqiu, Yang, Nan, Liu, Hailing, Yao, Huan, Wang, Jin, Yang, Yun, Zhang, Wanggang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096276/ https://www.ncbi.nlm.nih.gov/pubmed/30127892 http://dx.doi.org/10.3892/ol.2018.9018 |
Ejemplares similares
-
Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020) -
Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
por: DENG, QI, et al.
Publicado: (2015) -
Clinical efficacy of decitabine in combination with standard-dose cytarabine, aclarubicin hydrochloride, and granulocyte colony-stimulating factor in the treatment of young patients with newly diagnosed acute myeloid leukemia
por: Dou, Liping, et al.
Publicado: (2019) -
Immunological effects of vaccines combined with granulocyte colony-stimulating factor on a murine WEHI-3 leukemia model
por: Chen, Jinqiu, et al.
Publicado: (2017) -
Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation
por: Chen, Si-Si, et al.
Publicado: (2021)